{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"090-163-049-530-389","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"090-163-049-530-389"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10709,"type":"PATENT","title":"Rockefeller University Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":4213,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8226,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"Rockefeller University\"; \"Univ* Rockefeller\"; \"Univ* Rockef*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4020
Search Applicants and Owners separately: \"Rockefeller University\"; \"Univ* Rockefeller\"; \"Univ* Rockef*\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4020
a) generating a cytokine mediated matured dendritic cell population by subjecting immature dendritic cells to a cytokine cocktail comprising IL-1β, IL-6, TNF-α, and PGE2;\n
b) contacting the matured dendritic cells with KRN-7000 to reach at least a 60% maturity as expressed by % CD83+ cells, and\n
c) contacting the cells in (b) with an NKT cell population,\n
d) expanding the NKT cell population in said subject to at least 100 NKT cells per 1×106 lymphocytes in peripheral blood."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said KRN-7000 is at a concentration ranging from 1-1,000 ng/ml."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein said dendritic cells are present in or isolated from a subject having a carcinoma or myeloma."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["A method for expanding an NKT cell population in vivo, said method comprising:\n
a) generating a cytokine mediated matured dendritic cell population by subjecting immature dendritic cells to a cytokine cocktail comprising IL-1β, IL-6, TNF-α, and PGE2;\n
b) contacting the matured dendritic cells with KRN-7000 to reach at least a 60% maturity as expressed by % CD83+ cells, and\n
c) administering the cells in (b) to a subject,\n
d) allowing the contacting of said cells in (b) with the NKT cell population of said subject, whereby said NKT cell population undergoes expansion in said subject for a period of at least two months, following the administering step (b)."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said KRN-7000 is at a concentration ranging from 1-1,000 ng/ml."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 4, wherein said dendritic cells are present in or isolated from a subject having a carcinoma or myeloma."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["A method for stimulating or enhancing an immune response in a subject, said method comprising:\n
a) generating a cytokine mediated matured dendritic cell population by subjecting immature dendritic cells to a cytokine cocktail comprising IL-1β, IL-6, TNF-α, and PGE2;\n
b) contacting the matured dendritic cells with KRN-7000 to reach at least a 60% maturity as expressed by % CD83+ cells, and\n
c) administering the cells in (b) to a subject,\n
d) allowing the contacting of said cells in (b) with the NKT cell population of said subject, whereby said NKT cell population undergoes expansion to yield at least 100 NKT cells per 1×106 lymphocytes in peripheral blood of said subject and said NKT cell population participates in said immune response."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein said KRN-7000 is at a concentration ranging from 1-1000 ng/ml."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein said dendritic cells are isolated from a subject having a carcinoma or myeloma."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein said immature dendritic cells are isolated from a subject with an infection or a disease."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein said infection is viral."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, further comprising the step of contacting said NKT cell population in (d) with a second antigen presenting cell."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 12, further comprising the step of contacting said NKT cell population with a vaccine."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said vaccine comprises antigens derived from a pathogen."],"number":14,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 13, wherein said vaccine comprises antigens predominantly or preferentially expressed in neoplastic cells or tissue."],"number":15,"annotation":false,"title":false,"claim":true},{"lines":["A method for suppressing or reducing the severity of a tumor in a subject, comprising the steps of:\n
a) isolating immature dendritic cells from a subject having tumor,\n
b) generating a cytokine mediated matured dendritic cell population by subjecting said immature dendritic cells to a cytokine cocktail comprising IL-1β, IL-6, TNF-α, and PGE2;\n
c) contacting the matured dendritic cells with KRN-7000 to reach at least a 60% maturity as expressed by % CD83+ cells, and\n
d) administering the cells in (c) to a subject,\n
e) allowing the contacting of said cells in (c) with the NKT cell population of said subject, whereby said NKT cell population undergoes expansion to yield at least 100 NKT cells per 1×106 lymphocytes in peripheral blood of said subject and said NKT cells participate in an anti-neoplastic response in said subject."],"number":16,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said subject is post at least one course of cancer therapy and has preneoplastic or hyperplastic cells or tissue."],"number":17,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 16, wherein said subject is immunosuppressed or immunocompromised."],"number":18,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}